Suzhou Zelgen Biopharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-03-18
- Employees
- 867
- Market Cap
- -
- Website
- https://www.zelgen.com
Clinical Trials
75
Active:4
Completed:30
Trial Phases
4 Phases
Phase 1:42
Phase 2:19
Phase 3:12
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (75 trials with phase data)• Click on a phase to view related trials
Phase 1
42 (56.0%)Phase 2
19 (25.3%)Phase 3
12 (16.0%)Not Applicable
2 (2.7%)Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma
Not Applicable
Not yet recruiting
- Conditions
- Biliary Tract Carcinoma
- Interventions
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT07099547
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Not Applicable
Not yet recruiting
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT07080216
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Small Cell Lung CancerNeuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 350
- Registration Number
- NCT07038096
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT07024277
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Shanghai, Shanghai, China
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: ZGGS18 for InjectionBiological: ZG005 for Injection
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06938880
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
No news found